瑞舒伐他汀对急性冠脉综合征病人血高敏C反应蛋白水平的影响

Effects of Rosuvastatain on High Sensitivity C-reactive Protein of Patients with Acute Coronary Syndrome

目的观察不同剂量瑞舒伐他汀对急性冠脉综合征(ACS)病人高敏C反应蛋白(hs-CRP)水平的影响。方法选取我院150例ACS住院病人,随机分为3组。在常规治疗基础上,A组予瑞舒伐他汀5mg,每晚1次顿服;B组予瑞舒伐他汀10mg,每晚1次顿服;C组予辛伐他汀20mg,每晚1次顿服。分别于服药前及服药第4周、8周抽血检测血hs-CRP,观察其治疗疗效。结果治疗前3组间血hs-CRP水平差异无统计学意义(P>0.05);治疗4周后A组、C组病人血hs-CRP水平较治疗前略下降(P>0.05),B组较治疗前明显下降(P<0.05);服药8周后3组hs-CRP水平较前均明显下降(P<0.05),B组较A组、C组下降明显(P<0.05)。结论 10mg/d瑞舒伐他汀降低ACS病人hs-CRP的效果更明显,从而提示此剂量瑞舒伐他汀可能更有效地控制ACS的发生。

Objective To observe effects of rosuvastatain on high sensitivity C- reactive protein（hs CRP） of patients with acute coronary syndrome. Methods One hundred and fifty hospitalized patients with acute coronary syndrome were randomly divided into three groups,A group （rosuvastatain,5 mg/d）,B group （rosuvastatain,10 rag/d）,and C groups （simvastatin,20 rag/d）. The treat ment lasted for 8 weeks, bs CRP was tested before and 4,8 weeks after treatment. The hs - CRP was compared before and after treatment in three groups. Results There are no significant difference in the level of hs - CRP in three groups（P〉0.05）. After treatment for 4 weeks, bs - CRP in A, C groups is lower than before treatment slightly（P〉0. 05）. After treatment for 4 weeks,hs - CRP in B groups is lower than before treatment（P〈0.05）. After treatment for 8 weeks, hs - CRP in three groups are lower than before treatment （P〈0.05）. After treatment for 8 weeks, hs -CRP in B groups is lower compared to A and C groups （P〈0.05）. Conclusion Effects of 10 mg/d rosuvastatain were better than 5 mg/d rosuvastatain and 20 mg/d simvastatin on hs - CRP of patients with acute coronary syndrome,this dose rosuvastatain could effectively control morbidity of ACS.